Overview

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research

Status:
RECRUITING
Trial end date:
2027-04-05
Target enrollment:
Participant gender:
Summary
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Non-Hodgkin lymphoma
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Zhejiang University
Collaborator:
Leman Biotech Co., Ltd.